Vaxcyte, Inc. (NASDAQ:PCVX) is Novo Holdings A S’s 8th Largest Position

Novo Holdings A S decreased its holdings in Vaxcyte, Inc. (NASDAQ:PCVX) by 21.1% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 750,000 shares of the company’s stock after selling 200,000 shares during the period. Vaxcyte makes up about 4.3% of Novo Holdings A S’s holdings, making the stock its 8th biggest holding. Novo Holdings A S owned approximately 0.67% of Vaxcyte worth $85,702,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. raised its holdings in Vaxcyte by 15.2% during the 1st quarter. Vanguard Group Inc. now owns 9,737,254 shares of the company’s stock valued at $665,152,000 after buying an additional 1,284,883 shares during the last quarter. RA Capital Management L.P. raised its holdings in Vaxcyte by 4.0% during the 1st quarter. RA Capital Management L.P. now owns 8,203,754 shares of the company’s stock valued at $560,398,000 after buying an additional 312,500 shares during the last quarter. Janus Henderson Group PLC raised its holdings in Vaxcyte by 9.9% during the 1st quarter. Janus Henderson Group PLC now owns 7,673,868 shares of the company’s stock valued at $524,117,000 after buying an additional 692,492 shares during the last quarter. Capital Research Global Investors raised its holdings in Vaxcyte by 20.4% in the 1st quarter. Capital Research Global Investors now owns 4,140,521 shares of the company’s stock worth $282,839,000 after purchasing an additional 700,414 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its holdings in Vaxcyte by 18.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,176,181 shares of the company’s stock worth $216,966,000 after purchasing an additional 498,359 shares in the last quarter. Hedge funds and other institutional investors own 96.78% of the company’s stock.

Vaxcyte Trading Up 0.6 %

Shares of NASDAQ PCVX opened at $112.94 on Friday. The firm’s 50-day moving average price is $106.09 and its 200-day moving average price is $84.30. The stock has a market capitalization of $12.29 billion, a price-to-earnings ratio of -26.39 and a beta of 0.99. Vaxcyte, Inc. has a 12-month low of $45.61 and a 12-month high of $121.06.

Vaxcyte (NASDAQ:PCVX) last announced its earnings results on Tuesday, August 6th. The company reported ($1.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.14) by $0.04. During the same quarter in the previous year, the firm earned ($0.70) EPS. On average, equities analysts predict that Vaxcyte, Inc. will post -4.33 EPS for the current fiscal year.

Insider Activity

In other Vaxcyte news, CEO Grant Pickering sold 15,000 shares of the firm’s stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $78.98, for a total value of $1,184,700.00. Following the completion of the sale, the chief executive officer now owns 478,888 shares of the company’s stock, valued at $37,822,574.24. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other Vaxcyte news, CFO Andrew Guggenhime sold 8,000 shares of the firm’s stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $115.94, for a total value of $927,520.00. Following the completion of the sale, the chief financial officer now owns 90,383 shares of the company’s stock, valued at $10,479,005.02. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Grant Pickering sold 15,000 shares of Vaxcyte stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $78.98, for a total transaction of $1,184,700.00. Following the sale, the chief executive officer now directly owns 478,888 shares of the company’s stock, valued at $37,822,574.24. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 92,098 shares of company stock worth $9,937,773. 3.10% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research analysts have commented on PCVX shares. Jefferies Financial Group upped their price objective on shares of Vaxcyte from $108.00 to $129.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Bank of America raised their price target on shares of Vaxcyte from $101.00 to $140.00 and gave the company a “buy” rating in a report on Wednesday, September 4th. Leerink Partners increased their price objective on shares of Vaxcyte from $106.00 to $153.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 3rd. BTIG Research raised their target price on shares of Vaxcyte from $98.00 to $160.00 and gave the stock a “buy” rating in a research note on Tuesday, September 3rd. Finally, Needham & Company LLC lifted their price objective on shares of Vaxcyte from $95.00 to $140.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, Vaxcyte presently has an average rating of “Buy” and an average price target of $147.50.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.